11Jan 2023
Immune signatures in cutaneous melanoma correlate with survival independently of immunotherapy treatment

Immune signatures in cutaneous melanoma correlate with survival independently of immunotherapy treatment

Immune checkpoint inhibitors (ICIs) have improved survival from advanced cutaneous melanoma. Significant efforts have been made to understand the ICI response to identify ways to improve outcomes further. One such approach has been to investigate gene expression associated with response to ICI, which has identified various immune‐related mRNA signatures, including a 6‐gene IFN‐γ signature (IFN‐γ6), an expanded immune signature (IFN‐γ18), an effector T‐cell gene signature (Teff), and a Teff‐associated and IFN‐γ‐associated gene signature (Teff + IFN‐γ). The signatures were not present in melanoma cell lines compared with tumor samples, confirming that the signatures were likely derived from the samples’ non-tumor (immune) components. All four signatures were significantly associated with survival in 4/5 cohorts, with hazard ratios ranging from 0.69 to 0.92. The study findings conclude that these immune signatures’ association with survival is not specific to ICI-treated patients but present in several settings.

  • #dermatology

Like

Save

Share